Article Text

Download PDFPDF
An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis
  1. Claire Manginot1,
  2. Cédric Baumann2,
  3. Laurent Peyrin-Biroulet1,3
  1. 1Department of Hepato-Gastroenterology, University Hospital of Lorraine, Vandoeuvre-lès-Nancy, France
  2. 2ESPRI-BIOBASE Unit, University Hospital of Nancy, Vandoeuvre-lès-Nancy, France
  3. 3Inserm U954, Genetic nutrition and exposure to environmental risks (NGERE), University of Lorraine, Vandoeuvre-lès-Nancy, France
  1. Correspondence to Dr Laurent Peyrin-Biroulet, Department of Gastroenterology, Inserm U954, Université de Lorraine, Allée du Morvan, Vandœuvre-lès-Nancy 54 511, France; peyrinbiroulet{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dear Sir,

In a recent article1 we showed that correlation between histological indexes is strong for ulcerative colitis (UC). Due to the lack of intervention studies and the absence of a validated histological index, histological healing cannot be considered as a treatment goal in clinical practice for these patients. Pending these studies, we need to define the therapeutic goal for patients with UC.

In the ACT 1 and 2 clinical trials,2 early mucosal healing defined by an endoscopic Mayo score (EMS) of 0–1 was associated with a lower risk of colectomy through 54 weeks of follow-up evaluation and better long-term outcomes related to symptomatic remission, corticosteroid-free symptomatic remission and corticosteroid use, and subsequent mucosal healing at weeks 30 and 54. With the exception of colectomy …

View Full Text


  • Contributors CM, collected data, interpretation of data, drafting of the manuscript; CB, analysis and interpretation of data, drafting of the manuscript; LP-B, conception and design of study, interpretation of data, drafting of the manuscript.

  • Competing interests LP-B: consulting fees from Merck, Abbott, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Shire, Therakos, Pharmacosmos, Pilège, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Boerhinger-Ingelheim, Lilly, Pfizer. Lecture fees from Merck, Abbott, Janssen, Ferring, Norgine, Tillots, Vifor, Therakos, HAC-pharma. CM and CB declare no conflicts of interest.

  • Ethics approval CNIL declaration.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Data sharing statement We agree to share our data.

Linked Articles

  • Inflammatory bowel disease
    Aude Bressenot Julia Salleron Claire Bastien Silvio Danese Camille Boulagnon-Rombi Laurent Peyrin-Biroulet